DOT1L and breast carcinoma: DOT1L-specific inhibitors 1 and 2 were found to have strong activity against proliferation of DOT1L+ breast cancer cells with EC50 values as low as 190 nM, but these compounds were inactive against DOT1L−/low breast or non-breast cancer cells.